Nasal Polyps Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major nasal polyps markets reached a value of US$ 68.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 109.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.3% during 2024-2034.
The nasal polyps market has been comprehensively analyzed in IMARC's new report titled "Nasal Polyps Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nasal polyps refer to a medical condition in which there are soft, painless growths on the lining of the nasal passage or sinuses. They are noncancerous and often occur in the area where the sinuses open into the nasal cavity. Nasal polyps can be single or multiple and vary in size from small to large. The common symptoms of this ailment include a runny nose, persistent stuffiness, postnasal drip, decreased or absent sense of smell, facial pain, frequent nosebleeds, headache, snoring, pain in the upper teeth, a sense of pressure over the forehead and face, etc. The diagnosis of the illness is typically based on the patient’s medical history, clinical features, and a general physical test. Nasal endoscopy is further recommended in patients for a detailed examination of the nose and sinuses. The healthcare professional may also perform imaging studies, such as a computerized tomography (CT) scan, to evaluate the location and size of polyps in deeper areas of the sinuses and rule out other possible blockages in the nasal cavity.
The rising cases of allergies or infections, which trigger long-term inflammation and irritation in the nasal passage, are primarily driving the nasal polyps market. Moreover, the increasing incidence of genetic mutations associated with immune system functioning that result in the formation of abnormally thick, sticky mucus from the nasal and sinus linings is also bolstering the market growth. In addition to this, the widespread adoption of intranasal corticosteroid injections, like fluticasone, over conventional oral drugs on account of their improved efficacy profiles and lower risk of systemic side effects, is acting as another significant growth-inducing factor. Furthermore, the escalating demand for image guided endoscopic sinus surgery, which helps to improve precision, reduce complications, and enhance surgical outcomes in patients, is also creating a positive outlook for the market. Additionally, the rising popularity of biological drugs for treating the ailment, as they work by targeting specific proteins or cells to reduce swelling and irritation in the nasal passage, is expected to drive the nasal polyps market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the nasal polyps market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nasal polyps and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nasal polyps market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the nasal polyps market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the nasal polyps market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current nasal polyps marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the nasal polyps market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the nasal polyps market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the nasal polyps market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of nasal polyps across the seven major markets?
What is the number of prevalent cases (2018-2034) of nasal polyps by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of nasal polyps by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with nasal polyps across the seven major markets?
What is the size of the nasal polyps patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of nasal polyps?
What will be the growth rate of patients across the seven major markets?
Nasal Polyps: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for nasal polyps drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nasal polyps market?
What are the key regulatory events related to the nasal polyps market?
What is the structure of clinical trial landscape by status related to the nasal polyps market?
What is the structure of clinical trial landscape by phase related to the nasal polyps market?
What is the structure of clinical trial landscape by route of administration related to the nasal polyps market?
The nasal polyps market has been comprehensively analyzed in IMARC's new report titled "Nasal Polyps Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nasal polyps refer to a medical condition in which there are soft, painless growths on the lining of the nasal passage or sinuses. They are noncancerous and often occur in the area where the sinuses open into the nasal cavity. Nasal polyps can be single or multiple and vary in size from small to large. The common symptoms of this ailment include a runny nose, persistent stuffiness, postnasal drip, decreased or absent sense of smell, facial pain, frequent nosebleeds, headache, snoring, pain in the upper teeth, a sense of pressure over the forehead and face, etc. The diagnosis of the illness is typically based on the patient’s medical history, clinical features, and a general physical test. Nasal endoscopy is further recommended in patients for a detailed examination of the nose and sinuses. The healthcare professional may also perform imaging studies, such as a computerized tomography (CT) scan, to evaluate the location and size of polyps in deeper areas of the sinuses and rule out other possible blockages in the nasal cavity.
The rising cases of allergies or infections, which trigger long-term inflammation and irritation in the nasal passage, are primarily driving the nasal polyps market. Moreover, the increasing incidence of genetic mutations associated with immune system functioning that result in the formation of abnormally thick, sticky mucus from the nasal and sinus linings is also bolstering the market growth. In addition to this, the widespread adoption of intranasal corticosteroid injections, like fluticasone, over conventional oral drugs on account of their improved efficacy profiles and lower risk of systemic side effects, is acting as another significant growth-inducing factor. Furthermore, the escalating demand for image guided endoscopic sinus surgery, which helps to improve precision, reduce complications, and enhance surgical outcomes in patients, is also creating a positive outlook for the market. Additionally, the rising popularity of biological drugs for treating the ailment, as they work by targeting specific proteins or cells to reduce swelling and irritation in the nasal passage, is expected to drive the nasal polyps market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the nasal polyps market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nasal polyps and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nasal polyps market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the nasal polyps market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the nasal polyps market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current nasal polyps marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the nasal polyps market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the nasal polyps market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the nasal polyps market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of nasal polyps across the seven major markets?
What is the number of prevalent cases (2018-2034) of nasal polyps by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of nasal polyps by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with nasal polyps across the seven major markets?
What is the size of the nasal polyps patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of nasal polyps?
What will be the growth rate of patients across the seven major markets?
Nasal Polyps: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for nasal polyps drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nasal polyps market?
What are the key regulatory events related to the nasal polyps market?
What is the structure of clinical trial landscape by status related to the nasal polyps market?
What is the structure of clinical trial landscape by phase related to the nasal polyps market?
What is the structure of clinical trial landscape by route of administration related to the nasal polyps market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NASAL POLYPS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NASAL POLYPS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NASAL POLYPS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NASAL POLYPS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NASAL POLYPS - UNMET NEEDS
10 NASAL POLYPS - KEY ENDPOINTS OF TREATMENT
11 NASAL POLYPS - MARKETED PRODUCTS
11.1 List of Nasal Polyps Marketed Drugs Across the Top 7 Markets
11.1.1 Dupixent (Dupilumab) - Regeneron/Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Xolair (Omalizumab) - Genentech/Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Xhance (Fluticasone propionate intranasal) - OptiNose
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NASAL POLYPS - PIPELINE DRUGS
12.1 List of Nasal Polyps Pipeline Drugs Across the Top 7 Markets
12.1.1 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ACT 774312 - Idorsia Pharmaceuticals Ltd.
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NASAL POLYPS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NASAL POLYPS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NASAL POLYPS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Nasal Polyps - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Nasal Polyps - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Nasal Polyps - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Nasal Polyps - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Nasal Polyps - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Nasal Polyps - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Nasal Polyps - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Nasal Polyps - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Nasal Polyps - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Nasal Polyps - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Nasal Polyps - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Nasal Polyps - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Nasal Polyps - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Nasal Polyps - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Nasal Polyps - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Nasal Polyps - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Nasal Polyps - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Nasal Polyps - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Nasal Polyps - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Nasal Polyps - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Nasal Polyps - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Nasal Polyps - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Nasal Polyps - Access and Reimbursement Overview
16 NASAL POLYPS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NASAL POLYPS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NASAL POLYPS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NASAL POLYPS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NASAL POLYPS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NASAL POLYPS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NASAL POLYPS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NASAL POLYPS - UNMET NEEDS
10 NASAL POLYPS - KEY ENDPOINTS OF TREATMENT
11 NASAL POLYPS - MARKETED PRODUCTS
11.1 List of Nasal Polyps Marketed Drugs Across the Top 7 Markets
11.1.1 Dupixent (Dupilumab) - Regeneron/Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Xolair (Omalizumab) - Genentech/Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Xhance (Fluticasone propionate intranasal) - OptiNose
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NASAL POLYPS - PIPELINE DRUGS
12.1 List of Nasal Polyps Pipeline Drugs Across the Top 7 Markets
12.1.1 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ACT 774312 - Idorsia Pharmaceuticals Ltd.
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NASAL POLYPS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NASAL POLYPS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NASAL POLYPS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Nasal Polyps - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Nasal Polyps - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Nasal Polyps - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Nasal Polyps - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Nasal Polyps - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Nasal Polyps - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Nasal Polyps - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Nasal Polyps - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Nasal Polyps - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Nasal Polyps - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Nasal Polyps - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Nasal Polyps - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Nasal Polyps - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Nasal Polyps - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Nasal Polyps - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Nasal Polyps - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Nasal Polyps - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Nasal Polyps - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Nasal Polyps - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Nasal Polyps - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Nasal Polyps - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Nasal Polyps - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Nasal Polyps - Access and Reimbursement Overview
16 NASAL POLYPS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NASAL POLYPS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NASAL POLYPS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
